5-HT4 receptor agonist treatment of chronic constipation

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chronic constipation and irritable bowel syndrome (IBS) with constipation affect patient quality of life and are associated with a high healthcare expenditure. Conventional therapies for chronic constipation have limited effectiveness. New-generation, selective 5-HT4 receptor agonists are effective for chronic constipation, but none are currently approved in the U.S.; prucalopride is approved for the treatment of chronic constipation in Europe. The 5-HT4 receptor agonist velusetrag is being developed for chronic constipation and IBS with constipation; it has high selectivity and affinity for the 5-HT4 receptor. Velusetrag accelerates colonic transit in a dose-related manner, with a dose of 30 mg daily being the most effective over 9 days of treatment in healthy controls. In patients with chronic constipation, velusetrag increased spontaneous bowel movements after 4 weeks of therapy, with no serious cardiac events reported. Velusetrag has shown great promise, and further studies in chronic constipation and IBS with constipation are warranted.

Original languageEnglish (US)
Pages (from-to)447-454
Number of pages8
JournalDrugs of the Future
Volume36
Issue number6
DOIs
StatePublished - 2011

Fingerprint

Serotonin 5-HT4 Receptor Agonists
Receptors, Serotonin, 5-HT4
Constipation
Irritable Bowel Syndrome
Therapeutics
prucalopride
Health Expenditures

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

5-HT4 receptor agonist treatment of chronic constipation. / Vazquez Roque, Maria I; Camilleri, Michael.

In: Drugs of the Future, Vol. 36, No. 6, 2011, p. 447-454.

Research output: Contribution to journalArticle

@article{fe5ae4e26f704b2e803d78e1ed02ecd5,
title = "5-HT4 receptor agonist treatment of chronic constipation",
abstract = "Chronic constipation and irritable bowel syndrome (IBS) with constipation affect patient quality of life and are associated with a high healthcare expenditure. Conventional therapies for chronic constipation have limited effectiveness. New-generation, selective 5-HT4 receptor agonists are effective for chronic constipation, but none are currently approved in the U.S.; prucalopride is approved for the treatment of chronic constipation in Europe. The 5-HT4 receptor agonist velusetrag is being developed for chronic constipation and IBS with constipation; it has high selectivity and affinity for the 5-HT4 receptor. Velusetrag accelerates colonic transit in a dose-related manner, with a dose of 30 mg daily being the most effective over 9 days of treatment in healthy controls. In patients with chronic constipation, velusetrag increased spontaneous bowel movements after 4 weeks of therapy, with no serious cardiac events reported. Velusetrag has shown great promise, and further studies in chronic constipation and IBS with constipation are warranted.",
author = "{Vazquez Roque}, {Maria I} and Michael Camilleri",
year = "2011",
doi = "10.1358/dof.2011.036.06.1594078",
language = "English (US)",
volume = "36",
pages = "447--454",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "6",

}

TY - JOUR

T1 - 5-HT4 receptor agonist treatment of chronic constipation

AU - Vazquez Roque, Maria I

AU - Camilleri, Michael

PY - 2011

Y1 - 2011

N2 - Chronic constipation and irritable bowel syndrome (IBS) with constipation affect patient quality of life and are associated with a high healthcare expenditure. Conventional therapies for chronic constipation have limited effectiveness. New-generation, selective 5-HT4 receptor agonists are effective for chronic constipation, but none are currently approved in the U.S.; prucalopride is approved for the treatment of chronic constipation in Europe. The 5-HT4 receptor agonist velusetrag is being developed for chronic constipation and IBS with constipation; it has high selectivity and affinity for the 5-HT4 receptor. Velusetrag accelerates colonic transit in a dose-related manner, with a dose of 30 mg daily being the most effective over 9 days of treatment in healthy controls. In patients with chronic constipation, velusetrag increased spontaneous bowel movements after 4 weeks of therapy, with no serious cardiac events reported. Velusetrag has shown great promise, and further studies in chronic constipation and IBS with constipation are warranted.

AB - Chronic constipation and irritable bowel syndrome (IBS) with constipation affect patient quality of life and are associated with a high healthcare expenditure. Conventional therapies for chronic constipation have limited effectiveness. New-generation, selective 5-HT4 receptor agonists are effective for chronic constipation, but none are currently approved in the U.S.; prucalopride is approved for the treatment of chronic constipation in Europe. The 5-HT4 receptor agonist velusetrag is being developed for chronic constipation and IBS with constipation; it has high selectivity and affinity for the 5-HT4 receptor. Velusetrag accelerates colonic transit in a dose-related manner, with a dose of 30 mg daily being the most effective over 9 days of treatment in healthy controls. In patients with chronic constipation, velusetrag increased spontaneous bowel movements after 4 weeks of therapy, with no serious cardiac events reported. Velusetrag has shown great promise, and further studies in chronic constipation and IBS with constipation are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84952985517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952985517&partnerID=8YFLogxK

U2 - 10.1358/dof.2011.036.06.1594078

DO - 10.1358/dof.2011.036.06.1594078

M3 - Article

VL - 36

SP - 447

EP - 454

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 6

ER -